RESEARCH TRIANGLE PARK, N.C., Sept. 3, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present at two biotech conferences in September.
|22nd Annual NewsMakers in the Biotech Industry|
|Location: Millennium Broadway Hotel & Conference Center, New York, NY|
|Presentation date and time: Thursday, September 10 at 3 p.m. EDT|
|For additional information, please visit: http://www.biocentury.com/conferences/newsmakers/dates.|
|BioPharm America™ 2015|
|Location: Boston Marriott Copley Place, Boston, MA|
|Presentation date and time: Wednesday, September 16 at 3 p.m. EDT|
|For additional information, please visit: http://www.ebdgroup.com/bpa/index.php.|
About G1 Therapeutics, Inc.
G1 Therapeutics, Inc. is a privately held clinical-stage pharmaceutical company based in Research Triangle Park, NC that focuses on the discovery and development of novel, small-molecule therapies to address significant unmet needs in oncology. The company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates that address two markets: CDK4/6 antineoplastics and protection of the bone marrow and immune system from damage by chemotherapy (chemoprotection).
Visit www.g1therapeutics.com for more information.
Source: G1 Therapeutics